miR-504 expression level is increased in multiple sclerosis patients responder to interferon-beta

Multiple sclerosis is immune-mediated disease of the central nervous system characterized by demyelination in axons. IFN-beta is first-line treatment of MS. Biomarkers are needed for early prediction of responders and nonresponders to therapy in the first month of treatment to avoid further disabilities. In this study, we analyzed the expression level of miR-504 and miR-711 in 52 IFN-beta responder patients in comparison to 53 non-responders. In the next step, the in-silico analysis was used to enrich related signaling pathways. The expression level of miR-504 was significantly higher in patients who respond to IFN-beta therapy, compared with non-responders and we obtain related statistically significant KEGG molecular signaling pathways. Our findings suggest that miR-504 can be considered as a novel biomarker for response to IFN-b therapy.